Salazar Resources Limited (SRL) Sets Oct Drill Start at Yumi; Monja Drilling Planned 2027

Salazar Resources Limited (TSXV:SRL, OTCQB:SRLZF, FSE:CCG) says its Monja copper-gold porphyry footprint is 1.5 km by 0.5 km, with 64% of 99 rock samples above 300 ppm Cu and top grades including 1.71% Cu and 0.99 g/t Au. Ecuador’s ARCOM issued Resolution ARCOM-006/26 exempting exploration-stage projects from a 2026 oversight fee. Salazar also cites an independent SRK report confirming El Domo after-tax NPV of US$573m (8% discount), up from US$259m in 2021, and a July 24 Canada-Ecuador free trad

Salazar Resources Limited (TSXV: SRL, OTCQB: SRLZF) reported an updated NI 43-101 Technical Report for its Curipamba-El Domo polymetallic project in Ecuador, prepared by SRK Consulting for operator Silvercorp Metals (75%). Salazar’s 25% carried interest. After-tax NPV(8%) is US$573m, up 121% vs the 2021 feasibility study. Construction is fully funded, first production expected mid-2027.

Teck Resources Limited reported a strike at its Highland Valley Copper mine in British Columbia, reducing operations. The impact on production depends on the strike's duration. The company has contingency plans and aims for a fair collective agreement. Teck warned of potential effects on previously issued guidance due to the labor disruption.

Teck Resources Limited reports a strike at its Highland Valley Copper mine, leading to reduced operations. Production impact remains uncertain, depending on the strike's duration, according to the company.

Moderna and Merck's melanoma vaccine trial showed a 42% reduction in tumor recurrence and 38% in distant spread, impressing doctors. However, shares of both companies fell as investors questioned the vaccine's broader potential and commercial success. Analysts raised concerns about costs and competition. The full data will be presented at a medical conference.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.